We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+150.31%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.06B
AUM Growth
+$412M
Cap. Flow
+$25.7M
Cap. Flow %
2.41%
Top 10 Hldgs %
48.66%
Holding
270
New
60
Increased
70
Reduced
50
Closed
53

Top Buys

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$27.6M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$20.5M
3
ROIV icon
Roivant Sciences
ROIV
+$17.4M
4
ETNB
89bio
ETNB
+$12.6M
5
JANX icon
Janux Therapeutics
JANX
+$7.04M

Top Sells

Rank Stock Value
1
ABVX
Abivax
ABVX
+$105M
2
PRTA icon
Prothena Corp
PRTA
+$14.6M
3
CGON icon
CG Oncology
CGON
+$7.97M
4
SAGE
Sage Therapeutics
SAGE
+$6.58M
5
VERV
Verve Therapeutics
VERV
+$5.27M

Sector Composition

Rank Sector Weight
1 Healthcare 83.19%
2 Financials 1.65%
3 Communication Services 0.09%
4 Consumer Discretionary 0.09%
5 Technology 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHVN icon
151
CALL
Biohaven
BHVN
$2.21B
$375K 0.04%
25,000
– –
GH icon
152
Guardant Health
GH
$22.6B
$375K 0.04%
+6,000
New +$326K
BHVN icon
153
Biohaven
BHVN
$2.21B
$365K 0.03%
24,341
-8,000
-25% -$116K
OLMA icon
154
Olema Pharmaceuticals
OLMA
$1.05B
$354K 0.03%
+36,200
New +$217K
JD icon
155
JD.com
JD
$44.5B
$350K 0.03%
+10,000
New +$326K
LUNG icon
156
Pulmonx
LUNG
$87.6M
$347K 0.03%
214,497
+10,000
+5% +$20.9K
CNTX icon
157
Context Therapeutics
CNTX
$44.5M
$340K 0.03%
351,094
– –
JAZZ icon
158
Jazz Pharmaceuticals
JAZZ
$16.7B
$330K 0.03%
2,500
-250
-9% -$30K
AVTR icon
159
Avantor
AVTR
$9.19B
$312K 0.03%
25,000
+15,000
+150% +$193K
ANSC
160
Agriculture & Natural Solutions Acquisition Corp
ANSC
$476M
$296K 0.03%
27,062
– –
AKRO
161
DELISTED
Akero Therapeutics
AKRO
$292K 0.03%
6,143
-27,000
-81% -$1.31M
NRIX icon
162
Nurix Therapeutics
NRIX
$2.65B
$288K 0.03%
31,200
– –
PCAPU
163
ProCap Acquisition Corp Unit
PCAPU
$213M
$283K 0.03%
26,940
+16,260
+152% +$171K
HRMY icon
164
Harmony Biosciences
HRMY
$2.24B
$282K 0.03%
+10,245
New +$353K
RARE icon
165
Ultragenyx Pharmaceutical
RARE
$2.55B
$271K 0.03%
+9,000
New +$270K
CLYM
166
Climb Bio
CLYM
$802M
$268K 0.03%
133,530
+14,210
+12% +$26.4K
BMRN icon
167
BioMarin Pharmaceuticals
BMRN
$12.3B
$265K 0.02%
4,900
– –
VTYX
168
DELISTED
Ventyx Biosciences
VTYX
$254K 0.02%
81,600
-87,000
-52% -$230K
DYN icon
169
CALL
Dyne Therapeutics
DYN
$4.9B
$253K 0.02%
20,000
– –
OLMA icon
170
CALL
Olema Pharmaceuticals
OLMA
$1.05B
$245K 0.02%
+25,000
New +$150K
ALMS
171
Alumis Inc
ALMS
$3.52B
$245K 0.02%
61,291
+23,503
+62% +$96.8K
FLNA
172
Filana Therapeutics
FLNA
$48.1M
$236K 0.02%
+81,000
New +$186K
TXMD icon
173
TherapeuticsMD
TXMD
$24M
$225K 0.02%
209,210
– –
KALA icon
174
KALA BIO
KALA
$14.5M
$217K 0.02%
2,840
-157
-5% -$77.9K
SPRO icon
175
Spero Therapeutics
SPRO
$73M
$217K 0.02%
115,539
-28,378
-20% -$62.4K
5 6
7
8 9

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

ADAR1 Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, ADAR1 Capital Management held 270 positions worth $1.06B, up 63% from $652M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

ADAR1 Capital Management's Q3 2025 filing shows 60 new, 70 increased, 50 reduced and 53 closed positions. Its largest new stake was Invivyd: 7,370,987 shares worth $8.11M. The largest sale was Abivax, an estimated $105M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 79% a quarter earlier, followed by Financials and Communication Services.

  • ADAR1 Capital Management's largest Q3 2025 buy was Invivyd: 7,370,987 shares worth $8.11M.
  • ADAR1 Capital Management added most to Immunovant in Q3 2025, an estimated $27.6M increase.
  • ADAR1 Capital Management's biggest Q3 2025 reduction was Abivax, cutting an estimated $105M.
  • ADAR1 Capital Management fully exited Sage Therapeutics in Q3 2025, selling an estimated $6.58M.
  • ADAR1 Capital Management's ten largest holdings make up 49% of its $1.06B portfolio in Q3 2025.
  • ADAR1 Capital Management opened 60 new positions and closed 53 in Q3 2025.
  • ADAR1 Capital Management's portfolio value rose 63% quarter-over-quarter to $1.06B.

Based on ADAR1 Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.